SMOORE
23.9.2021 13:17:15 CEST | Business Wire | Press release
SMOORE, a global leader in offering vaping technology solutions, today has made its mark at The Global Tobacco & Nicotine Forum (GTNF) 2021. Senior Vice President of SMOORE and President of FEELM, the flagship atomization tech brand belonging to SMOORE, Frank Han makes the keynote speech to outline SMOORE’s mission of “atomization making life better.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005511/en/
The Global Tobacco & Nicotine Forum (GTNF) is the world’s leading annual forum discussing the future of the tobacco and nicotine industries. The annual industry conference brings together key stakeholders from around the world, including global tobacco companies, vaping brands, scientists, public health experts, NGOs and policymakers.
In his speech, Frank Han calls upon all stakeholders of the industry to join the mission of “atomization making life better”, promoting the evolution of atomization ecosystem . He asserts that policymakers and NGOs should take the lead in institutional innovations to promote the healthier industry development and more balanced regulations, embracing vaping as a strategy to improve public health while safeguarding against youth vaping. Global media could also involve more people in the unbiased public dialogue on vaping.
Moreover, industry leaders should work together to build up more comprehensive industry standards. As one of the key industry standard setters, SMOORE has developed its vapor and material safety standards, which involve over 300 physical and chemical tests. These standards have also covered all of PMTA tests and the safety evaluation of over 50 atomization materials, thereby guaranteeing industry-leading product quality.
In terms of product innovation , Frank Han indicates that the underlying technology of vaping—atomization, has showed promising prospects in other fields, such as healthcare. With one of its R&D focus on the atomization application in healthcare, SMOORE has made significant progress on the research of atomized medication in the past three years.
“In the near future, more and more people will inhale medicines or vaccines with atomization devices. It could help the world pull through the pandemic,” said Frank Han.
According to Frank Han, SMOORE’s innovations are based on its insights into global consumers’ requirements and the commitment to improving user experience, which is the company’s first principle of product development. Based on the principle, SMOORE launched the world’s first Taste Evaluation Model in 2020, covering 4 dimensions and 51 indexes, so as to establish a scientific system to evaluate vaping tastes.
Moreover, Frank Han points out that scientific innovation is the driving force of the industry’s evolution. Industry pioneers are constantly committed to the cross-disciplinary fundamental research of “atomization science”, to explore the mechanism of atomization.
As the world’s leading atomization tech platform, SMOORE has recruited R&D experts from different backgrounds and built up 7 global research centers around the world. In addition to in-house R&D resources, SMOORE has partnered with top universities to leverage the latest scientific discoveries and transform them into cutting–edge applied technologies.
The industry is also embracing intelligent manufacturing to improve resource efficiency. For example, SMOORE introduced the first fully automated pod production line in the world. Now, a single line of SMOORE can produce 7,200 standard vaporizers per hour.
In partnership with clients, SMOORE has also adopted sustainable practices in all stages of product development, especially manufacturing, so as to fulfill its commitment to reducing carbon footprint.
“Innovation and sustainability are the ideas to which the whole industry has been adhering, since the advent of vaping. The two ideas share a common goal, that is ‘atomization making life better’, which echoes SMOORE’s corporate mission,” said Frank Han.
Committed to the mission of “Atomization making life better”, SMOORE will continue to discover more diversified atomization methods and more advanced technology roadmap while jointly promoting a more inclusive dialogue mechanism along with partners from different sectors.
About SMOORE
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base. The Company is the world's largest vaping device manufacturer in terms of revenue, accounting for 18.9% of the total global market share.
About FEELM
FEELM is a high-end atomization technology brand belonging to SMOORE. Focusing on the research of cutting-edge atomization technology, FEELM also specializes in the development and manufacturing of high quality atomization devices driven by FEELM ceramic coil. “FEELM inside” symbol is on the closed system pods of a number of global leading tobacco companies and vaping companies around the world. The accumulated sales volume of FEELM has surpassed 3 billion pieces per year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005511/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
